Comparison of combined low-dose hormone therapy vs. tibolone in the prevention of bone loss

Objectives: To compare the effects on bone mineral density (BMD) measured by dual-energy X-ray absorptiometry at the lumbar spine, the femoral neck and the total hip following 2 years of treatment with a low-dose combined hormone therapy (HT) comprised of 1 mg estradiol and 0.5 mg norethisterone ace...

Full description

Saved in:
Bibliographic Details
Published in:Climacteric : the journal of the International Menopause Society 2016-10, Vol.19 (5), p.471-477
Main Authors: Kalder, M., Kyvernitakis, I., Hars, O., Kauka, A., Hadji, P.
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Bone density
Bone Density - drug effects
bone mineral density
Drug dosages
Endocrine therapy
Estradiol - administration & dosage
Estradiol - adverse effects
Estrogen Replacement Therapy
Female
Health risk assessment
Hormone replacement therapy
Hormone therapy
Humans
Middle Aged
Norethindrone - administration & dosage
Norethindrone - adverse effects
Norpregnenes - administration & dosage
Norpregnenes - adverse effects
osteoporosis
Osteoporosis, Postmenopausal - prevention & control
Preventive medicine
Prospective Studies
Side effects
Steroids
tibolone
Uterine Hemorrhage - etiology
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To compare the effects on bone mineral density (BMD) measured by dual-energy X-ray absorptiometry at the lumbar spine, the femoral neck and the total hip following 2 years of treatment with a low-dose combined hormone therapy (HT) comprised of 1 mg estradiol and 0.5 mg norethisterone acetate (E2/NETA) versus 2.5 mg tibolone in postmenopausal women. Additionally, quantitative ultrasonometry (QUS) of the os calcaneus and of the phalanges was performed. Methods: Changes in BMD, QUS and side-effects were assessed at baseline, 6, 12 and 24 months in 50 postmenopausal women who received either E2/NETA (n = 26) or tibolone (n = 24) for 2 years. Results: Compared to women on tibolone, women receiving E2/NETA showed a significant increase in BMD from baseline to 12 and 24 months at the lumbar spine (3.07%, 3.86%; p 
ISSN:1369-7137
1473-0804
DOI:10.1080/13697137.2016.1198313